COMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference
10 avr. 2023 10h10 HE
|
COMPASS Pathways
LONDON, April 10, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference
02 mars 2023 10h23 HE
|
COMPASS Pathways
LONDON, March 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
28 févr. 2023 07h00 HE
|
COMPASS Pathways
Highlights: Phase 3 pivotal program underway - important updates announcedPhase 3 long term follow up definedCash position at 31 December 2022 of $143.2 millionConference call today at 8:00am ET...
COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023
24 févr. 2023 12h01 HE
|
COMPASS Pathways
LONDON, Feb. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
08 déc. 2022 04h00 HE
|
COMPASS Pathways
12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II...
COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference
28 nov. 2022 16h01 HE
|
COMPASS Pathways
LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
03 nov. 2022 07h00 HE
|
COMPASS Pathways
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Highlights: Phase 3 pivotal program design finalized and on track to start in 2022; several clinical sites have been initiatedPhase 2b trial data...
COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine
03 nov. 2022 06h00 HE
|
COMPASS Pathways
After a single 25mg dose of COMP360 psilocybin therapy, approximately 30% of patients with treatment-resistant depression (TRD) were in remission at week 3 Sustained response seen through week...
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
26 oct. 2022 16h00 HE
|
COMPASS Pathways
LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day
12 oct. 2022 11h00 HE
|
COMPASS Pathways
LONDON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...